Spiriva

Primary Uses

Spiriva is prescribed for the long-term maintenance treatment of several respiratory conditions. It is intended for daily use to keep airways open over time rather than providing immediate relief.

• Chronic Obstructive Pulmonary Disease (COPD): It is used to treat bronchospasm (narrowing of the airways) associated with COPD, which includes chronic bronchitis and emphysema. Regular use helps to reduce the frequency of flare-ups or exacerbations.
• Asthma: It is used as a long-term, once-daily maintenance treatment for asthma in adults and children 6 years of age and older.

Maintenance vs. Rescue Treatment

It is important to note that this medication is not a rescue treatment. It will not work fast enough to stop a sudden asthma attack or a sudden episode of breathlessness. A separate fast-acting rescue inhaler is usually required for sudden symptoms.

Mechanism of Action

Spiriva belongs to a class of medications known as long-acting anticholinergics or muscarinic antagonists. It works by targeting specific receptors in the smooth muscles of the airways.

In the body, a natural chemical called acetylcholine can cause the muscles surrounding the bronchial tubes to tighten or constrict. Spiriva blocks the action of this chemical. When these muscles relax, the airways widen, a process called bronchodilation. This allows more air to flow in and out of the lungs.

Long-Term Maintenance

Because Spiriva is a long-acting medication, its effects typically last for at least 24 hours. This helps provide consistent airway opening throughout the day and night. It is used as a maintenance treatment to prevent symptoms rather than as a rescue inhaler for sudden breathing problems. Regular use helps manage daily symptoms such as:

• Shortness of breath
• Wheezing
• Coughing
• Chest tightness

Common Side Effects

Many people using Spiriva experience mild side effects. These may include:

• Dry mouth
• Sore throat or cough
• Sinus pain or congestion
• Constipation
• Indigestion or stomach pain
• Muscle aches
• Fast or irregular heartbeat

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious side effects:

• Allergic reactions: Symptoms may include rash, hives, itching, or swelling of the face, lips, tongue, or throat.
• Vision problems: Eye pain, blurred vision, redness of the eye, or seeing halos around lights. These may be signs of narrow-angle glaucoma.
• Urinary issues: Difficulty urinating, painful urination, or passing less urine than usual, especially in patients with an enlarged prostate.
• Paradoxical bronchospasm: Sudden wheezing or trouble breathing immediately after using the inhaler.

Not for Acute Use

Spiriva is intended for long-term maintenance treatment and is not a rescue medication. It should not be used for the immediate relief of sudden breathing problems or acute bronchospasm.

Allergic Reactions

Immediate hypersensitivity reactions may occur after administration. These can include rash, hives, swelling of the lips, tongue, or throat (angioedema), and anaphylaxis. If signs of a serious allergic reaction appear, the medication should be stopped immediately.

Paradoxical Bronchospasm

Like other inhaled medicines, Spiriva can cause a sudden, life-threatening worsening of breathing (paradoxical bronchospasm) immediately after use. If this occurs, the medication should be discontinued and alternative treatments should be explored.

Worsening of Narrow-Angle Glaucoma

Spiriva may worsen narrow-angle glaucoma. Patients should be alert for signs such as eye pain or discomfort, blurred vision, visual halos, or colored images in association with red eyes. Medical attention should be sought if these symptoms develop.

Urinary Retention

Caution is advised for patients with prostatic hyperplasia or bladder-neck obstruction. Spiriva may worsen symptoms of urinary retention, such as difficulty passing urine or painful urination.

Renal Impairment

Because the medication is primarily excreted by the kidneys, patients with moderate to severe renal impairment (creatinine clearance of 60 mL/min or less) should be monitored closely for potential side effects.

Proper Administration

Spiriva HandiHaler capsules are for oral inhalation only and must be used with the HandiHaler device. The capsules should never be swallowed.

Pregnancy

There are no adequate and well-controlled studies on the use of Spiriva (tiotropium) in pregnant women. In animal studies, very high doses of the medication were associated with adverse effects on fetal development; however, these doses were much higher than those used in humans. Because the risks to a human fetus are not fully known, this medication should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the unborn baby.

Breastfeeding

It is not known whether tiotropium passes into human breast milk. While animal studies have shown that the drug is excreted in the milk of lactating rats, there is no data available for humans. Because many medications can pass into breast milk, caution should be exercised when using Spiriva while nursing.

Consult Your Healthcare Provider

If you are pregnant, planning to become pregnant, or breastfeeding, it is important to discuss your treatment with a healthcare professional. They can help you weigh the benefits of controlling your respiratory symptoms against any potential risks to your baby.

Available Forms

Spiriva is provided in two distinct delivery systems designed for oral inhalation:

• Inhalation Powder: This form consists of capsules containing a dry powder. These capsules are intended for use only with the HandiHaler inhalation device. The device pierces the capsule so the powder can be inhaled through the mouthpiece. These capsules must never be swallowed.
• Inhalation Spray: This form uses a cartridge that is inserted into the Respimat inhaler. The device delivers the medication as a slow-moving mist that is inhaled through the mouth.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) has approved Spiriva in two primary formulations: Spiriva HandiHaler and Spiriva Respimat. Both are indicated for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. Additionally, Spiriva Respimat is FDA-approved for the maintenance treatment of asthma in adults and children aged 6 years and older.

Spiriva is not intended for the treatment of acute episodes of bronchospasm, also known as rescue therapy.

Safety Communications

The FDA previously conducted a safety review regarding a potential increased risk of stroke, heart attack, or cardiovascular death in patients using tiotropium. Following a large-scale clinical trial known as the UPLIFT study, the FDA concluded that the available data did not demonstrate an increased risk of these cardiovascular events associated with the use of Spiriva HandiHaler.

Regulatory Status

• Boxed Warning: Spiriva does not carry an FDA boxed warning.
• REMS: There is no Risk Evaluation and Mitigation Strategy (REMS) required for this medication.
• Controlled Substance: Tiotropium is not a controlled substance.

Factors Influencing Cost

The price you pay for Spiriva can vary based on several factors, including the specific delivery system prescribed. Spiriva is available as the HandiHaler, which uses dry powder capsules, and the Respimat, which is a propellant-free spray. These different formulations may have different price points at the pharmacy.

Insurance and Generic Availability

Insurance coverage is a primary factor in determining out-of-pocket expenses. Most Medicare Part D and private insurance plans include tiotropium on their formularies, though the copayment amount will depend on your specific plan's tier system. A generic version of the Spiriva HandiHaler is available, which is generally less expensive than the brand-name version. Generic options for the Respimat formulation may be more limited.

Financial Assistance Options

There are several ways to potentially reduce the cost of this medication:

• Manufacturer Savings: The drug manufacturer may offer savings cards or coupons for patients with commercial insurance that can lower monthly copays.
• Patient Assistance Programs: Programs are often available for individuals who do not have insurance or who meet specific low-income requirements.
• Pharmacy Discounts: Some retail pharmacies offer discount programs or work with third-party savings platforms to provide lower prices for those paying out of pocket.